RNAi News incorrectly reported last week that CytRx CEO Steven Kriegsman had stated than an investigational new drug application for an siRNA-based amyotrophic lateral sclerosis treatment is expected to be filed in the second half of 2005.
Although the company’s earlier goal of filing an IND before the end of 2004 was dropped, a new timeline has not been established.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.